The article focuses on the efficacy of cervical cancer vaccines under review by regulatory agencies. Several drug manufacturers are expecting a decision on its licensure application to the U.S. Food and Drug Administration. The vaccine from GlaxoSmithKline PLC was already proven effective in clinical trials.